WHAT IS CLAIMED IS:

1. Use of a combination of an EZH2 modulator and an anti-CD19 antibody, in the manufacture of a medicament for the treatment of a cancer in a human subject.

2. Use of an EZH2 modulator in the manufacture of a medicament for the treatment of a cancer in a human subject, wherein the EZH2 modulator is to be administered in combination with an anti-CD19 antibody.

3. Use of an anti-CD19 antibody in the manufacture of a medicament for the treatment of a cancer in a human subject, wherein the anti-CD19 antibody is to be administered in combination with an EZH2 modulator.

4. The use of any one of claims 1-3, wherein the EZH2 modulator is of the chemical formula:



or a pharmaceutically acceptable salt thereof.

5. The use of any one of claims 1-4, wherein the anti-CD19 antibody comprises a heavy chain variable region comprising an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), and an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3) and a light chain variable region comprising the sequence LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).

6. The use of any one of claims 1-5, wherein the anti-CD19 antibody comprises a heavy chain variable region of EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVF DYWGQGTLVTVSS (SEQ ID NO: 7) and a light chain variable region of DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEI K (SEQ ID NO: 8).

7. The use of any one of claims 1-6, wherein the anti-CD19 antibody comprises an Fc domain comprising an amino acid substitution at position S239 and/or I332, wherein the numbering is according to the EU index as in Kabat.

8. The use of any one of claims 1-6, wherein the anti-CD19 antibody comprises an Fc domain comprising an S239D amino acid substitution and an I332E amino acid substitution, wherein the numbering is according to the EU index as in Kabat.

9. The use of any one of claims 1-8, wherein the anti-CD19 antibody comprises a heavy chain region of EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVF DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK KVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK (SEQ ID NO: 11) and a light chain region of DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ

ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12)

10. The use of any one of claims 1-9, wherein the medicament comprising the EZH2 modulator is to be administered orally.

11. The use of any one of claims 1-9, wherein the medicament comprising the EZH2 modulator is to be administered intravenously, or subcutaneously.

12. The use of any one of claims 1-9, wherein the EZH2 modulator, is to be administered by intravenous infusion.

13. The use of any one of claims 1-12, wherein the cancer is a CD19 positive cancer.

14. The use of any one of claims 1-13, wherein the cancer is a hematological malignancy.

15. The use of any one of claims 1-14, wherein the cancer is a lymphoma or a leukemia.

16. The use of any one of claims 1-15, wherein the cancer is chronic lymphocytic leukemia, acute lymphoblastic leukemia, or a non-Hodgkin's lymphoma.

17. The use of any one of claims 1-16, wherein the cancer is a non-Hodgkin's lymphoma selected from the group consisting of follicular lymphoma (FL), small lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma.